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Background: Chronic obstructive pulmonary disease (COPD) severity is usually graded
upon the FEV1 reduction and FEV1 has been considered the most important mortality
predictor with age in COPD. Recent studies suggest other factors as more powerfully
related to mortality than FEV1 in COPD patients.
Aim: To assess the impact of inspiratory capacity (IC) on mortality and morbidity in COPD
patients during a 5-year follow-up period.
Methods: We recruited 222 patients with mild-to-moderate COPD from January 1995 to
December 2001 with an average follow-up period of 60 months (range 30–114 months).
Among different respiratory parameters measured in stable conditions FEV1, FEV1/FVC%,
IC and PaO2, PaCO2 and BMI were chosen and their relationships with all-cause and
respiratory mortality and with morbidity were assessed.
Results: All these variables were associated with mortality at the univariate analysis.
However, in a multivariate regression analysis (Cox proportional hazards model) for
all-cause mortality age (year), IC (%pred.) and PaO2 (mmHg) remained the only signi-
ficant, independent predictors (HR ¼ 1.056, 95%CI: 1.023–1.091; HR ¼ 0.981, 95%CI:
0.965–0.998; HR ¼ 0.948, 95%CI: 0.919–0.979, respectively). According to the same
analysis, IC (%pred.) and PaO2 (mmHg) were significant independent predictors for
respiratory mortality (HR ¼ 0.967, 95%CI: 0.938–0.997; HR ¼ 0.919, 95%CI: 0.873–0.969)
together with FEV1/FVC% and BMI (kg/m
2) (HR ¼ 0.967, 95%CI: 0.933–1.022; HR ¼ 0.891,
95%CI: 0.807–0.985, respectively). IC (%pred.), FEV1/FVC%, and PaO2 (mmHg) were also
significantly related to morbidity, as independent predictors of hospital admissions
because of exacerbations (OR ¼ 0.980, 95%CI: 0.974–0.992; OR ¼ 0.943, 95%CI:
0.922–0.987; OR ¼ 0.971, 95%CI: 0.954–0.996, respectively).Elsevier Ltd. All rights reserved.
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C. Tantucci et al.614Conclusion: IC (%pred.) is a powerful functional predictor of all-cause and respiratory
mortality and of exacerbation-related hospital admissions in COPD patients.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive lung disease (COPD) is one of the most
frequent causes of death in developed countries.1 The
forced expiratory volume in the first second (FEV1) has been
considered for a long time the most relevant predictor of
mortality with age in COPD and the COPD severity is
generally based on the degree of airway obstruction as
assessed by FEV1.
2,3 Some authors, however, questioned this
way to graduate such a complex disorder, recognizing the
necessity of a multidimensional approach to COPD. Indeed,
Celli et al. proposed a composite index including several
parameters such as body mass index, airflow obstruction,
dyspnea, exercise performance, called BODE index, to
stratify the severity of COPD remarking that BODE index
was stronger than FEV1 to predict survival in a large cohort
of COPD patients.4 However, the BODE index encompasses
causes and effects of COPD, being indoubtedly chronic
dyspnoea and exercise tolerance the consequences of the
disease. In the attempt to better focus on the physio-
pathological changes occurring in the COPD patients as
determinants of the prognosis of the disease Casanova et al.
identified the ratio between inspiratory capacity (IC) and
total lung capacity (TLC) as a powerful predictor of
mortality in COPD.5 In fact, IC, reflecting changes in
functional residual capacity (FRC), may signal, when
reduced, the presence of static (SH) and/or dynamic (DH)
pulmonary hyperinflation at rest and during effort.6 DH is
presently believed to be the mechanism explaining larger
part of chronic dyspnea and limited tolerance to exercise in
COPD,7,8 and its increase is likely associated with the
worsening of the lung function in these patients. The IC/TLC
ratio was chosen to normalize the absolute IC for each
patient, because of the lack of IC predicted values.
However, computation of the IC/TLC ratio implies accurate
measurement of TLC that in COPD patients can be
adequately performed only with body plethysmograph.
This greatly limits a widespread use of this parameter to
predict survival in the COPD patients. Recently, we pro-
vided the equations to compute the predicted values for IC
in the elderly people.9 Therefore, the aim of the study was
to assess the ability of IC to predict mortality and morbidity
in a population of the COPD patients followed in our
institution.
Methods
We prospectively evaluated a cohort of COPD patients at the
Respiratory Medicine Unit of the Department of Internal
Medicine of the University of Brescia between January 1995
and December 2001. The diagnosis of COPD was made
according to the following criteria: (i) smoking history of
more than 20 pack-years and/or presence of other known
risk factors for COPD; (ii) baseline FEV1/VC ratio lower than88% and 89% predicted in men and women, respectively10;
(iii) increase of FEV1 lesser than 12% of baseline and 200ml
after 400mcg of inhaled salbutamol; (iv) no history or
evidence of other diseases with chonic airflow obstruction
such as asthma, bronchiectasies, bronchiolitis, tubercolosis
and cystic fibrosis. COPD patients with history of relevant
comorbidities other than systemic arterial hypertension
were excluded. No hypertensive COPD patients, however,
had a history of severe hypertension and all were regularly
taking anti-hypertensive drugs. At the time of recruitment
none of them had high blood pressure values.
At least 24-h after withdrawal of long-acting beta-2
agonists, anticholinergics and theophilline, in the absence
of exacerbation in the preceding 6 weeks, the patients
underwent clinical evaluation with determination of
BMI, pulmonary functional testing (spirometry, maximal
flow/volume curve) (System 1070, Medical Graphics, St.
Paul, MN, USA) and sampling of arterial blood gases at rest,
in the supine position during air breathing to measure
PaO2 and PaCO2. All spirometric parameters (FEV1, FVC)
were analyzed as percent of predicted values.10 IC was
measured as shown in our recent paper and its pre-
dicted values computed according to the following predic-
tion equations: A(0.030)+H(2.047)+BMI(0.075)0.372
for males and A(0.030)+H(2.553)+BMI(0.037)0.709 for
females, where A is the age in years, H is the height in
meters and BMI is the body mass index in kilograms
per square meter.9 Predicted values of IC for those patients
aged less than 65 were obtained back-extrapolating the
above-mentioned equations. The patients were recruited
if able to perform correctly the pulmonary function tests
according to the ATS guidelines.11 Two hundred and twenty-
two patients satisfied these criteria (126 males and 96
females). Sixty-nine patients were younger than 65 years
at the entry of the study, none older than 85. Most patients
had been regularly followed up by periodic clinical
and functional evaluation. In the remaining cases, we have
had a direct contact with the patients, their relatives
and their family doctors to get the clinical records. In case
of death, hospital records or death certificates were
obtained to ascertain the cause of death. Patients gave
their verbal informed consent to the collection of their
personal data.
Both overall mortality and mortality for respiratory
causes were evaluated. In addition, morbidity was assessed
by the number of hospitalizations that occurred during the
follow-up period, due to worsening of dyspnea, increase of
cough and/or expectoration with or without fever, and
occurrence of any other symptom or sign related to the
exacerbation of the disease.
The follow-up ended in August 2004; the mean follow-up
period was 60 months (range 30–114 months). All patients
assumed bronchodilators, some of them were taking inhaled
corticosteroids, while only a minority was placed on long-
term oxygen therapy.
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Data were expressed as mean7S.D. The baseline character-
istics of the study patients who died and those who
remained alive were compared by using the unpaired
Student’s t-test for continuous variables and the w2
Pearson’s test for categorical variables. To analyze all-cause
and respiratory mortality the Cox proportional hazard model
was used. All the variables associated with mortality at the
univariate analysis were included in the Cox regression
proporzional hazards model to estimate the independent
power of each one in predicting all-cause and respiratory
mortality, according to a computer-driven backward step-
wise multiple linear regression analysis. The survival curves
of Kaplan–Meyer were performed for both all-cause and
respiratory mortality according to the model of comparison
between two sample groups and the differences between
the curves were evaluated by the log-rank tests. To assess
the role of each respiratory and anthropometric parameter
as predictor of the number of hospital admissions we
considered this number as a response variable at four
categories, from 0 to 3+. Logistic regression models with
ordered categories in this response variable were then fitted
using the proportional odds model. At a first step, all the
investigated parameters were included in the model to
evaluate the role of each of them when taking account of
any other. Only those significant at the 0.05 p-level were
retained using a backward strategy in the final model. The
proportion odds assumption was assessed by comparing
the odds ratios between adjacent categories of the
dichotomized response variable (0 vs. all the others, 0–1
vs. 2 and over).
Receiver operating characteristic (ROC) type II curves
were also obtained, estimating the C statistics for each one,
to compare how more precise is the IC than the FEV1 and
FEV1/FVC ratio to predict all-cause mortality. A p-value less
than 0.05 was considered statistically significant. The
calculations were made using the SPSS 14.0 statistic package
(SPSS, Chicago, IL).Results
Two hundred and twenty-two COPD patients (126 males and
96 females) of whom 139 current smokers, with a mean ageTable 1 Baseline characteristics of all COPD patients and of th
All (n ¼ 222) Alive
Sex, M/F 126/96 78/7
Age (year) 67711 65
Smoker/non-smoker 139/83 88/6
FVC (%pred.) 90.1722.0 93.4
FEV1 (%pred.) 69.1725.6 74.0
FEV1/FVC (%) 60.1714.8 63.2
IC (%pred.) 82.8722.7 87.1
PaO2 (mmHg) 7179.3 72.2
PaCO2 (mmHg) 41.375.8 39.8
BMI (kg/m2) 25.573.2 26.0of 67711 years (range 59–85 years) and a mean BMI of
25.573.2 kg/m2 without comorbidities other than systemic
hypertension (n ¼ 81), were followed over a mean period of
60 months (range 30–114 months). The COPD patients were
classified according to the severity of airflow obstruction as
defined by the GOLD guidelines2: 80 (36%) were in stage I
(FEV1X80%pred.), 83 (37%) in stage II (FEV1 between
o80%pred. and X50%pred.), 44 (20%) in stage III (FEV1
betweeno50%pred. andX30%pred.) and 15 (7%) in stage IV
(FEV1o30%pred.). At entry time, FVC was 90722%pred.,
FEV1 was 69726%pred., FEV1/FVC ratio was 60715%, IC
amounted to 83723%pred. and PaO2 and PaCO2 were
7179mmHg and 4176mmHg, respectively. At the end of
the follow-up period, 73 (32.9%) patients were dead and 149
were still alive. Among the COPD patients who died, 42 had
FEV1450%pred. at the beginning of the study (26% of
mortality in stages I and II), while 31 had FEV1o50%pred.
(53% of mortality in stages III and IV).
Among 73 patients who died, 34 (46.5%) died because of
respiratory failure, 20 (27.4%) because of cardio- and
cerebro-vascular events, 18 (24.6%) because of cancer (10
for lung cancer) and one died because of bowel obstruction.
The differences between dead and alive patients are
shown in Table 1. Patients who died were older, had greater
airflow obstruction, more abnormal gas exchange and lower
IC and BMI. At the univariate Cox regression analysis all the
above-mentioned respiratory parameters were significantly
related to all-cause mortality and mortality for respiratory
causes. However, according to the multivariate Cox propor-
tional hazard regression model analysis only age and IC
(%pred.), and PaO2 (mmHg) remained significant predictors
of all-cause mortality (Table 2). At entry time, IC higher
than 80%pred. was found in 102 COPD patients and lower
than 80%pred. in 120 COPD patients. In this latter subgroup
21 over 80 (26%) COPD patients were in stage I, 47 over 83
(57%) in stage II, in 38 over 44 (88%) in stage III and in 14 over
15 (93%) in stage IV, respectively. In the follow-up, 22 COPD
patients with IC480%pred. (21.6%) and 51 COPD patients
with ICo80%pred. (42.5%) died. The Kaplan–Meier survival
curve for all-cause mortality related to IC, using the
80%pred. value as threshold, is shown in Figure 1(panel A).
Concerning the mortality due to respiratory causes (i.e.
respiratory failure), IC (%pred.), PaO2 (mmHg), FEV1/FVC
ratio and BMI (kg/m2) were independent predictors when
included in the multivariate Cox analysis (Table 3). Theose who remained alive and who died during the follow-up.
(n ¼ 149) Dead (n ¼ 73) p
1 48/25 0.26
711 7278 o0.0001
1 51/22 o0.05
721.1 80.8721.0 o0.0001
724.5 57.6722.9 o0.0001
714.1 53.9714.2 o0.0001
719.9 72.2721.8 o0.0001
78.5 66.278.9 o0.0001
74.2 43.977.1 o0.0001
73.0 24.473.25 o0.05
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Table 2 Predictors of all-cause mortality.
HR 95%CI p
IC (%pred.) 0.981 0.965–0.998 0.0266
Age (year) 1.056 1.023–1.091 0.0004
PaO2 (mmHg) 0.948 0.919–0.979 0.002
Abbreviations: IC, inspiratory capacity; PaO2, partial pres-
sure of oxygen in arterial blood. Relative hazards (HR), 95%
confidence interval (CI) values and p-values were determined
in the Cox proportional hazards model. All relative risks were
adjusted for sex and hypertensive condition; respiratory
parameters, age, PaCO2, PaO2, and BMI were analyzed in the
model as continuous variables. The HR values are intended
for unitary increase in age (year), IC (%pred.) and PaO2
(mmHg). The clinical meaning is that for any unitary decrease
in IC (%pred.) and PaO2 (mmHg), the risk of all-cause
mortality increases by about 2% and 5%, respectively.
C. Tantucci et al.616Kaplan–Meier curve for mortality due to respiratory causes is
shown for IC in Figure 1(panel B), using the same cut-off
value.
During the follow-up, 42 patients had one hospital
admission for exacerbation, 40 patients two and 47 patients
three or more, while 93 patients did not. Only IC (%pred.),
FEV1/FVC ratio and PaO2 (mmHg) were retained as sig-
nificant predictors of morbidity, assessed by the hospitaliza-
tion rate due to exacerbation, using the proportional odds
model after backward stepwise analysis in our COPD
population (Table 4).
The IC (%pred.), FEV1 (%pred.) and FEV1/FVC ratio ROC
type II curves as predictors of all-cause mortality are shown
in Figure 2, together with their under the curve area C
statistics.Discussion
The present study indicates for the first time that IC
(%pred.) is a powerful independent predictor of all-cause
mortality and mortality for respiratory cause in COPD
patients. Moreover, IC (%pred.) is a significant risk factor
for morbidity in these patients, at least in terms of number
of exacerbation-related hospitalizations. COPD patients
with IC lower than 80% of its own predicted in stable
conditions are at higher risk of mortality and disease-related
morbidity in the next 5 years. In our hands this index
appears to be the respiratory functional parameter with the
best sensitivity and specificity in predicting all-cause
mortality in a population of COPD patients with a wide
range of airway obstruction severity.
These findings are not unexpected. The IC when normal-
ized for plethysmographic TLC (IC/TLC ratio) has been
recently shown as an important mortality predictor in a
large multi-center cohort of COPD patients when IC was less
than 25% of TLC.5 Our data are in line with these results
underlying, however, the importance of the IC reduction,
reflecting both static and mainly dynamic pulmonary
hyperinflation, rather than of the TLC increase which
essentially reflects static pulmonary overinflation, as prog-
nostic risk factor in COPD.On the other hand, the measurement of IC is much easier
than the computation of the IC/TLC ratio for which a body
plethysmograph is needed, and the availability of reference
values for IC can make this index very useful in the
evaluation of disease.9
Unfortunately, we could not compare IC (%pred.) with
IC/TLC ratio (%) because TLC was not measured by body
plethysmograph in our COPD patients. However, IC has
better sensibility and specificity (and greater area under the
ROC curve) than IC/TLC ratio in predicting overall mortality
when our data are indirectly compared with those published
in a larger cohort of COPD patients with similar percentage
of mortality (33% vs. 27%).5
Presently, no longitudinal studies are available for IC in
COPD patients because of the lack of reliable prediction
equations, and although one study failed to show any
predictive capacity of IC in the 1-year all-cause mortality for
a similar cohort of COPD patients, the values of IC were
analyzed as absolute and not as % predicted.4
The IC change reflects the variation of the end expiratory
lung volume (EELV) that is the operative level (static or
dynamic) of the functional residual capacity (FRC). Hence,
the IC reduction is associated with an increase in the EELV,
heralding static and/or dynamic pulmonary hyperinflation.
While static hyperinflation is essentially related to a
decreased pulmonary elastance, conversely elevated venti-
latory demand, prolonged pulmonary time-constants, due to
high lung compliance and/or pulmonary and airway flow
resistance, and mostly tidal expiratory flow limitation at
rest (EFL) are responsible for DH in COPD patients.12,13 DH is
related to indices of neuro-mechanical uncoupling and of
exertional dyspnea during effort in stable COPD patients,
being the most relevant mechanism of exercise intolerance
in these patients with moderate-to-severe airflow obstruc-
tion.14,15 Accordingly, the baseline IC has been strongly
related to peak VO2 and carbon dioxide increase in COPD
patients during exercise, limiting their performance because
of tidal volume constraint and physiological dead space
increment.8,16 In addition, COPD patients with resting EFL
who usually show decreased IC, have more chronic dyspnea
and orthopnea.17,18
Moreover, Martinez et al. have shown that after lung
volume reduction surgery in COPD patients the exercise
tolerance and dyspnea amelioration in the follow-up was
better related to changes in the EELV than in FEV1,
suggesting that decrease in pulmonary hyperinflation rather
than in the airflow obstruction is important to improve
symptoms and related quality of life in these patients.19
How can these findings translate in a lesser survival in a
relatively short time, with an average relative risk for all-
cause and respiratory death with increases of 2% and 3%,
respectively, for 1% predicted of IC decrease in our COPD
patients (Tables 2 and 3), is unclear. Indeed, parameters
reflecting changes in lung volume, such as IC and IC/TLC
ratio, seem more sensitive and specific to predict mortality
in COPD patients than those reflecting the airflow obstruc-
tion, like FEV1 and FEV1/FVC%, as shown by the respective
ROC curves analysis (see Figures 2 and 3 in the Ref. 5). It is
presently unknown what links pulmonary hyperinflation
and a higher risk of mortality in COPD patients and this
topic will deserve greater attention in future researches.
More frequent exacerbations, early and deeper systemic
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Figure 1 Kaplan–Meier curves for all-cause (panel A) and respiratory mortality (panel B) in a group of 222 COPD patients who were
divided according to the presence of resting pulmonary hyperinflation measured by IC (%pred.), using 80%pred. as cut-off value. The
cumulative survival rate is significantly lower in the COPD patients with ICo80%pred. for both outcomes: (+) survivors and (J) non-
survivors.
Inspiratory capacity predicts COPD mortality 617involvement, higher and more sustained work of breathing
due to intrinsic PEEP, greater unbalance of the autonomic
nervous system could be hypothetic mechanisms to explore.
This is not just speculative because we have treatments
capable of reducing pulmonary hyperinflation (mainly
dynamic) in COPD patients even in stable conditions that
have been shown as effective in decreasing the exacerbation
rate in a long-term period.20–23
Although our cohort of COPD patients was relatively
small, its rigorous selection (no relevant comorbidities at
the entry), the mean duration of follow-up (60 months) and
the percentage of mortality (33%) make these results
consistent and applicable to larger similar COPD populations
seen in pulmonary function Laboratories.
FEV1 has been recognized as an important predictor of
mortality in COPD and so it was in our population, butseveral studies have shown that FEV1 is not the only
determinant of mortality and a number of risk factors have
been identified such as hypoxemia and a low BMI.24,25 This
was also the case in the present study. Recently, some lung
functional parameters such as the IC/TLC ratio5 and now IC
(%pred.) have proved to be powerful in predicting all-cause
and respiratory mortality, as documented by the ROC curves
analysis. Interestingly, these parameters reflect pulmonary
hyperinflation rather than airflow obstruction, being more
closely related to chronic dyspnea17 and tolerance to
exercise8,15 in COPD patients. Therefore, it is not surprising
that these two outcomes have been found as relevant
prognostic factors of survival in COPD patients, more
discriminating than FEV1 when adequately categorized,
26,27
and that dyspnea and exercise performance emerged as
significant independent variables to retain in the composite
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Table 3 Predictors of respiratory mortality.
HR 95%CI p
IC (%pred.) 0.967 0.938–0.997 0.031
PaO2 (mmHg) 0.919 0.873–0.969 0.001
FEV1/FVC (%) 0.967 0.933–1.022 0.083
BMI (kg/m2) 0.891 0.807–0.985 0.102
Definition of abbreviations as in Table 1. BMI, body mass
index. Relative hazards (HR), 95% confidence interval (CI)
values and p-values were determined in the Cox proportional
hazards model. All relative risks were adjusted for sex, and
hypertensive condition; respiratory parameters, age, PaO2,
PaCO2 and BMI were analyzed in the model as continuous
variables. The HR values are intended for unitary increase in
IC (%pred.), PaO2 (mmHg), FEV1/FVC (%) and BMI (kg/m
2).
The clinical meaning is that for any unitary decrease in IC
(%pred.), PaO2 (mmHg), FEV1/FVC (%) and BMI (kg/m
2), the
risk of respiratory mortality increases by about 3%, 8%, 3%
and 11%, respectively.
Table 4 Predictors of hospitalization rate for COPD
exacerbations.
OR 95%CI p-Level
IC (%pred.) 0.980 0.974–0.993 0.001
FEV1/FVC (%) 0.943 0.922–0.987 0.001
PaO2 (mmHg) 0.971 0.954–0.996 0.046
Definition of abbreviations as in Table 1. Odds ratios (OR),
95% confidence interval (CI) values and p-values were
determined according to a logistic regression model with
ordered categories for the number of hospital admissions
using the proportional odds model.
Figure 2 ROC type II curves and C statistics value for FEV1
(%pred.), IC (%pred.) and FEV1/FVC ratio as predictors of all-
cause mortality in patients with COPD. The sensitivity and
specificity of IC are greater than those of FEV1 and FEV1/FVC
ratio.
C. Tantucci et al.618BODE index in order to better predict mortality and so
graduate the severity of COPD.4 It is conceivable that
all these findings were largely functional consequences
of the pulmonary (mainly dynamic) hyperinflation the
severity of which, however, should be directly measured
by functional parameters such as IC/TLC ratio and, more
easily, IC.
In our COPD cohort, beside age and hypoxemia
(PaO2o60mmHg), BMI less than 25 kg/m2 was independent
predictor of respiratory mortality. These results are in
agreement with previous studies.25,28–30 In particular, a
retrospective study performed in 400 COPD patients showed
a significant increase in all-cause mortality after 48 months
when BMI was lower than 25 kg/m2 even after adjustment
for age, sex, FEV1, VC, PaO2 and PaCO2.
25 Moreover, when in
a large, randomly selected, COPD population the relation
between BMI and mortality was prospectively analyzed, an
independent effect of BMI was found on both all-cause and
COPD-related mortality, being a value of BMIo25 kg/m2
linked to a poor prognosis, especially in moderate-to-severe
COPD patients (FEV1o50%pred.).29 In a recent paper arising
from the data base of the Copenhagen City Heart Study
(CCHS), Vestbo et al. found in a large number of COPD
patients that a low fat-free mass-index (FFMIo10th per-
centile in CCHS controls), occuring in COPD patients not onlywith low BMI (o18.5 kg/m2) but also with normal BMI, was
an independent risk factor for all-cause mortality.30 Our
data suggest that in COPD patients without relevant co-
morbidities the negative prognostic effect of BMIo25 kg/m2
(and likely low FFMI) is substantially related to respiratory
mortality.
In conclusion, IC (%pred.) is a strong independent
predictor of all-cause and respiratory mortality and emerges
as a relevant risk factor for exacerbation-related hospita-
lization in COPD patients. These results indicate the need to
consider this simple volume-related functional parameter in
the evaluation of disease severity in patients suffering from
COPD.Conflict of interest statement
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